Efficacy of siltuximab in the treatment of idiopathic multicentric castleman disease, the first Polish, real-world experience with long-term observation

Leuk Lymphoma. 2021 Dec;62(12):3031-3034. doi: 10.1080/10428194.2021.1941926. Epub 2021 Jun 23.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Castleman Disease* / diagnosis
  • Castleman Disease* / drug therapy
  • Humans
  • Poland

Substances

  • Antibodies, Monoclonal
  • siltuximab

Supplementary concepts

  • Multi-centric Castleman's Disease